# **Original Article**

# Histologic and histomorphometric evaluation of the effect of lactoferrin combined with anorganic bovine bone on healing of experimentally induced bony defects on rabbit calvaria

#### Mojgan Paknejad<sup>1,2</sup>, Amir Reza Rokn<sup>2,3</sup>, Ali Akbar Sabur Yaraghi<sup>4</sup>, Flora Elhami<sup>1</sup>, Mohammad Javad Kharazifard<sup>5</sup>, Neda Moslemi<sup>6,7</sup>

<sup>1</sup>Dental Research Center, <sup>2</sup>Department of Periodontics, School of Dentistry, <sup>3</sup>Implant Research Center, <sup>4</sup>Department of Nutrition and Biochemistry, School of Public Health, <sup>5</sup>Biostatistician, Dental Research Center, <sup>6</sup>Laser Research Center in Dentistry, <sup>7</sup>Department of Periodontics, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran

#### ABSTRACT

**Background:** Recent studies have shown that lactoferrin promotes the proliferation and differentiation of osteoblasts and inhibits osteoclast-mediated bone resorption. Anorganic bovine bone (ABB) graft has been extensively used as an osteoconductive material in the bone reconstructive surgeries. The purpose of this study was to examine whether the combination of lactoferrin with Bio-Oss would improve ossification in experimentally induced bone defects in rabbit calvaria.

**Materials and Methods:** In this randomized, prospective animal study, a total of 32 bone defects with the diameter of 6 mm were created on the calvaria of 8 male New Zealand rabbits (4 defects in each animal). One defect was filled with ABB + Lactoferrin + Vehicle (BLV), the second one with ABB + Lactoferrin (BL), the third defect with ABB + V (BV), and the fourth defect was filled with ABB (B) alone. After 4 weeks, histologic sections were prepared and evaluated histologically and histomorphometrically. The type, percentage and vitality of newly formed bone, inflammation, percentage of residual material, and foreign body reaction were assessed for each specimen. Data were analyzed using Friedman tests.

Received: March 2012 Accepted: July 2012

Address for correspondence: Prof. Neda Moslemi, Ghods Street, Enghelabave, Post code: 14147, Tehran, Iran. E-mail: neda\_moslemi@ yahoo.com **Results:** All groups were similar in terms of inflammation and vitality, type, percentage of new bone formation, and residual material. The percentage of new bone formation in BLV, BL, BV, and B groups were  $14.73 \pm 3.14\%$ ,  $15.02 \pm 1.51\%$ ,  $15.95 \pm 2.24\%$  and  $13.44 \pm 2.89\%$  (P = 0.1) and the amount of residual biomaterial were  $11.85 \pm 1.50\%$ ,  $13.73 \pm 1.80\%$ ,  $13.02 \pm 1.86\%$ , and  $15.41 \pm 2.05\%$ , respectively (P = 0.392). **Conclusion:** Based on results of this study, the combination of lactoferrin and ABB did not show any significant improvement in bone regeneration compared with ABB alone in surgically induced bony defects in rabbit calvaria.

Key Words: Animal experimentation, bone regeneration, bovine bone, lactoferrin, osteogenesis

### INTRODUCTION

Milk is a rich biological fluid with many growth factors that have a critical role in skeletal growth and development of neonate.<sup>[1]</sup> Lactoferrin is a fraction of



whey protein that is extracted from milk. This agent not only has been found in milk, but also has been extracted from exocrine secretions of mammals and secondary granules of neutrophils. This iron-binding glycoprotein belongs to the transferrin family and has shown multifunctional properties that among them antimicrobial effects,<sup>[2]</sup> modulation of inflammatory and immune response,<sup>[3]</sup> and promotion of bone growth are prominent. *In vitro* studies showed that lactoferrin potently stimulates proliferation and differentiation of osteoblasts and inhibits apoptosis of osteoblasts and formation of osteoclasts.<sup>[4,5]</sup> It was demonstrated that lactoferrin promotes the ability of osteoblasts

Dental Research Journal / Dec 2012 / Vol 9 / Issue 7 (Supplement Issue 1)

to synthesize and mineralize bone matrix, as well.<sup>[1]</sup> A recent study showed that bovine lactoferrin induces synthesis of the angiogenic factors (vascular endothelial growth factor and fibroblast growth factor-2) in osteoblasts.<sup>[6]</sup> An in vivo study evaluated the effect of lactoferrin on bone mass. This study showed that subcutaneous injection of lactoferrin in mice resulted in dramatic increase in local bone formation.<sup>[4]</sup> Anorganic bovine bone (ABB) is an osteoconductive material that is used extensively for bone augmentation (Bio-Oss; Geistlich Biomaterials). Due to lack of osteoinductive properties of this bone graft, several agents have been combined to enhance its regenerative properties.<sup>[7]</sup> Bone morphogenic protein and platelet rich plasma are frequently used as osteoinductive agents;<sup>[8,9]</sup> however, some of their drawbacks like high cost and patient morbidity have limited their common uses in practice.<sup>[10]</sup>

To the best of our knowledge, no study has evaluated the effect of combination of lactoferrin and ABB in bone healing. The aim of this study was to evaluate the influence of addition of lactoferrin to ABB in comparison with ABB alone in regeneration of experimentally induced bony defect in rabbit calvaria.

# MATERIALS AND METHODS

Eight healthy 6-month old New Zealand white male rabbits with average weight of  $3.5 \pm 0.3$  kg were included in this randomized blind experimental study. The animal study protocol was approved by Ethical Committee for animal experiments of Tehran University of Medical Sciences. Each rabbit was anesthetized with an intramuscular injection of 0.75 mg/kg ketamine (Imalgene 1000<sup>®</sup>, Rhone Merieux, Toulouse, France) and 0.25 mg/kg xilacine (Rompun<sup>®</sup>, Bayer, Leverkusen, Germany). The animals were accommodated in separate cages and had free access to food and water from one month before surgical intervention.

Non-iron saturated bovine lactoferrin (Sigma Chemical Company; St. Louis, USA) was diluted in distilled water (1:10) to obtain the concentration of 500  $\mu$ g/ml.<sup>[11,12]</sup> Seventy-microliter lactoferrin was used in each defect.


Tragacanth was used as a vehicle for lactoferrin. Tragacanth has been proposed as a carrier for lactoferrin.<sup>[13]</sup> This natural gum is obtained from *Astragalus gummifer Labillardiere* and other species of *Astragalus* grown in western Asia. Tragacanth gum is used as a suspending and emulsifying agent in a variety of pharmaceutical formulations. Its wide use is due to its stability in a wide range of temperature and pH, and its effectiveness as an emulsifying agent with extremely long shelf life.<sup>[14]</sup> As tragacanth is a natural polymer, it is nontoxic and biocompatible, making it a suitable medium for cell growth.<sup>[15,16]</sup>

### Surgical procedure

The heads of animals were shaved, and the cutaneous surface was disinfected with povidone iodine solution prior to the operation. The calvaria bone was exposed through a skin incision of 10 cm in caudo-cranial direction. A periosteal elevator was used to separate the periosteum from the bone surface. Four similar circular bicortical defects (6-mm diameter) were made in the parietal bone using a trephine on a slow-speed electric handpiece with physiologic saline irrigation [Figure 1a]. For the first rabbit, randomly, one defect was filled with ABB + Lactoferrin + Vehicle (BLV), the second one with ABB + Lactoferrin (BL), the third defect with ABB + V (BV), and the fourth defect was filled with ABB (B) alone. For next ones the positions were changed rotationally (clockwise) [Figure 1b]. Closure of periosteum and subcutaneous tissues was done with 4/0 bioabsorbable polyglactin 910 suture (Vicryl, Ethicon Inc., Somerville, NJ), while the skin was relocated with Nylon 3/0 suture (Apositos Sanitarios Aragoneses, Huesca, Spain). After surgery, each animal received subcutaneous injection of Ketoprofen (0.1 ml daily for 3 days) and enrofloxacin (Baytril, Bayer Corp, Shawnee, KS, USA) (0.7 ml daily for 7 days). The animals were sacrificed with an overdose of sodium pentobarbital IV (Dolethal; Vetoquinol) after four weeks.

# Histology and histomorphometry

All samples were prepared for hematoxilin and eosin (H and E) staining. In each animal, the entire calvarium was removed using a reciprocating saw.



**Figure 1:** (a) Four bicortical defects (6-mm diameter) were made in the parietal bone using a trephine. (b) Defects were randomly filled with ABB+Lactoferrin+Vehicle, ABB+Lactoferrin, ABB+Vehicle, and ABB alone. (ABB: Anorganic bovine bone)

Samples were fixed in 10% buffered formalin for 2 weeks and then decalcified by immersion in nitric acid solution. Finally, samples were dipped in lithium carbonate solution for neutralization.

After bisecting each defect, specimens were dehydrated by graded alcohol and embedded in paraffin. Then, they were sectioned at 5-µm sections, stained with H and E, and examined under a light microscope (BX 51, Olympus Co., Tokyo, Japan). On average, three most central sections were obtained from each specimen for histologic and histomorphometric analyses. A masked, expert pathologist examined the following criteria in the histologic sections:

Inflammation was assessed based on inflammatory cell (IC) counts under a high power field (×40) as follows: grade 0 (no IC), grade 1 (1-100 IC), grade 2 (100-250 IC), grade 3 (more than 250 IC).<sup>[17]</sup>

Foreign body reaction was manifested as the presence of foreign body giant cells in a granulomatous response. The digital photographs were analyzed by Adobe Photoshop CS2 (Adobe Systems, San Jose, CA). In this analysis, the pixels within the marked area were counted using the software. The percentage of newly formed bone was calculated as follows: The number of pixels in the newly formed bone/total number of pixels in the defect  $\times$  100. Furthermore, the percentage of remaining material was calculated as the number of pixels in the area of remaining material/total number of pixels in the defect  $\times$  100.

#### **Statistical analysis**

The parameters were analyzed using Friedman test. Significance for the analyses were set at P < 0.05.

### RESULTS

Healing was uneventful in all cases. A mild inflammation (grade I) was seen in one of specimens in BL group and moderate inflammation (grade II) was seen in one of samples in BV group. Other specimens showed no inflammatory reaction.

Foreign body reaction was not observed in any specimen.

Type of newly formed bone was a mixture of woven and lamellar bone in all specimens.

Mean (SD) of percentage of new bone and residual material is demonstrated in Table 1. The differences between groups were not statistically significant with regard to the amount of new bone formation (P = 0.1).

In addition, four defects were not statistically different in terms of residual material (P = 0.392) [Figure 2a-d].


# DISCUSSION

The results of this study showed that addition of lactoferrin did not have any positive influence on the amount of new bone formation in experimentally induced bone defects in rabbit calvaria.

Table 1: Mean (SD) of percentage of new bone and			
residual material in experimental defects			

Treatment groups	Newly formed bone (%)	Remnant material (%)
B-L group	14.73±3.14	11.85±1.50
B-V group	15.02±1.51	13.73±1.80
B-L-V group	15.95±2.24	13.02±1.86
B group	13.44±2.89	15.41±2.05

B: Anorganic bovine bone, L: Lactoferrin, V: Vehicle



**Figure 2:** Hematoxylin and Eosin-stained section of defects. New bone formation and residual particles are observed in all defects (original magnification ×20). (a) ABB + Lactoferrin; (b) ABB + Vehicle; (c) ABB + Lactoferrin+ vehicle; (d) ABB alone. ABB: Anorganic bovine bone

Previous studies on rabbit calvaria stated that critical size defects in the range of 11-15 mm are suitable.<sup>[18-22]</sup> Analysis of the ability of different graft materials to create complete bone healing of a defect necessitates the use critical size defect, in order to prevent spontaneous bone regeneration. Since the present study was designed to investigate the early phases of regeneration, it was possible to use smaller defects. In addition, it is not possible to create four critical-size defects in rabbit calvaria, since it is too small. On the other hand, the results of a recent study showed that after 4 weeks, the percentage of new bone in 6 mm-defect was not different from 8 and 11 mm-defect. Furthermore, the authors suggested that four small defects could be used when early phase healing response of several materials are to be investigated.<sup>[23]</sup> In the present study, four defects were created in single animal to simultaneously compare several materials whilst avoiding inter-individual variation.

Several in vitro studies on lactoferrin and bone allowed direct contact of lactoferrin with bone cells.<sup>[1,4,24-26]</sup> However, to the best of our knowledge, this is the first animal study that used lactoferrin in direct contact with the defect. In previous animal studies, lactoferrin was administered orally or as subcutaneous injection.[4,12,27,28] With regard to inflammatory reaction, the results of the present study showed that most specimens (30 out of 32) showed no sign of inflammation and the addition of lactoferrin to Bio-Oss in the defects had no effect on inflammatory reactions of specimen. Regarding the inflammatory response to Bio-Oss, the result of this study is in accordance with other studies that reported no inflammatory reactions in defects filled with Bio-Oss.<sup>[29,30]</sup> Furthermore, this result confirms the previous findings, reported that lactoferrin modulates the inflammatory process, by regulating the proliferation and differentiation of immune cells and preventing the release of cytokines from monocytes.<sup>[31]</sup>

The percentages of remaining material were not significantly different between the study groups. However, B group showed slightly more, but not statistically significant, remaining material. This may be related to a fact that the surgical defect in B group was filled only with ABB and initially the volume of ABB (Bio-Oss) in B-group was higher than other groups. Therefore, this is not surprising that more material remained in B group after 1 month. The results of this study showed a slight more bone formation in BLV group (2.5% more new bone formation) in comparison with B group. However, this slight improvement was not statistically significant. The result of the present study is in accordance with that of Guo et al. study. To evaluate the effects of lactoferrin on bone loss in osteoporosis, lactoferrin was administered orally in ovariectomized rats. The authors indicated that although oral administration of lactoferrin attenuates estrogen-dependent trabecular bone loss in ovariectomized rats, this treatment did not alter the thickness of cortical bone in femoral diaphysis. The authors assumed that lactoferrin may be a more effective protecting agent against bone loss on the trabecular than cortical bone.<sup>[28]</sup> Noteworthily, calvaria consist mostly of cortical bone and this could partially explain the finding of this study that showed no detectable influence of lactoferrin in bone regeneration in experimentally induced bone defects in rabbit calvaria.

The current results are not in line with some other studies. Studies by Blais *et al.* showed that oral administration of lactoferrin decreased bone loss and bone resorption markers in ovariectomized rats<sup>[12]</sup> and this improvement was associated with modulation of immunological functions such as antigen presentation properties, T cell activation and down-regulation of cytokine molecules.<sup>[27]</sup>

In addition, Cornish *et al.* showed that subcutaneous injection of bovine lactoferrin for five consecutive days in mouse calvaria resulted in local bone formation after 10 days.<sup>[4]</sup> The influence of lactoferrin on bone growth might be apparent at earlier stages of healing. Since the specimens were prepared after 1 month in this study, the possible effects of lactoferrin cannot be evaluated in shorter intervals.

In the present study, lactoferrin was applied with a vehicle, in order to prevent washout of lactoferrin and to provide better sustain release properties. Noteworthily, although not significant difference, BV group showed more bone formation compared to B group (15.02% vs. 13.44%). No study was found to investigate the possible effects of tragacanth on bone regeneration. Tragacanth is a natural non-toxic gum. When solubilized in water, tragacanth forms viscous solutions. Tragacanth is among the most acid-resistant gums. The viscosity of tragacanth remains quite stable over a broad range (pH 2-10). Because of its high acid stability, the gum is widely used in acidic conditions in pharmaceutical industry.

Gum tragacanth is also an excellent emulsifying agent for oil-in-water emulsions. Tragacanth acts as a stabilizer for active ingredients of pharmaceutical products.<sup>[32]</sup> More new bone formation in defects filled with tragacanth may be due to the ability of this ingredient in stabilization of blood clot. The initial clot adhesion and wound stabilization is one of the most critical factors in wound healing sequence, which leads to predictable bone formation. The initial blood clot is a rich source of growth factors and signaling molecules that recruit clearing cells to the wound site.<sup>[33]</sup>

# CONCLUSION

Within the limitations of this study, it can be concluded that application of bovine lactoferrin in experimentally induced bone defect cannot accelerate new bone formation in rabbit calvaria.

### REFERENCES

- 1. Naot D, Grey A, Reid IR, Cornish J. Lactoferrin–a novel bone growth factor. Clin Med Res 2005;3:93-101.
- Vorland LH. Lactoferrin: A multifunctional glycoprotein. APMIS 1999;107:971-81.
- 3. Actor JK, Hwang SA, Kruzel ML. Lactoferrin as a natural immune modulator. Curr Pharm Des 2009;15:1956-73.
- Cornish J, Callon KE, Naot D, Palmano KP, Banovic T, Bava U, *et al.* Lactoferrin is a potent regulator of bone cell activity and increases bone formation *in vivo*. Endocrinology 2004;145:4366-74.
- Lorget F, Clough J, Oliveira M, Daury MC, Sabokbar A, Offord E. Lactoferrin reduces *in vitro* osteoclast differentiation and resorbing activity. Biochem Biophys Res Commun 2002;296:261-6.
- Nakajima K, Kanno Y, Nakamura M, Gao XD, Kawamura A, Itoh F, *et al.* Bovine milk lactoferrin induces synthesis of the angiogenic factors VEGF and FGF2 in osteoblasts via the p44/ p42 MAP kinase pathway. Biometals 2011;24:847-56.
- Sollazzo V, Palmieri A, Scapoli L, Martinelli M, Girardi A, Pezzetti F, *et al.* PerioGlas (R) acts on human stem cells isolated from peripheral blood. Dent Res J (Isfahan) 2010;7:28-34.
- Terheyden H, Jepsen S, Moller B, Tucker MM, Rueger DC. Sinus floor augmentation with simultaneous placement of dental implants using a combination of deproteinized bone xenografts and recombinant human osteogenic protein-1. A histometric study in miniature pigs. Clin Oral Implants Res 1999;10:510-21.
- Birang R, Torabi A, Shahabooei M, Rismanchian M. Effect of plasma-rich in platelet-derived growth factors on peri-implant bone healing: An experimental study in canines. Dent Res J (Isfahan) 2012;9:93-9.
- King GN, Cochran DL. Factors that modulate the effects of bone morphogenetic protein-induced periodontal regeneration: A critical review. J Periodontol 2002;73:925-36.

- Yamauchi K, Toida T, Nishimura S, Nagano E, Kusuoka O, Teraguchi S, *et al.* 13-Week oral repeated administration toxicity study of bovine lactoferrin in rats. Food Chem Toxicol 2000;38:503-12.
- Blais A, Malet A, Mikogami T, Martin-Rouas C, Tome D. Oral bovine lactoferrin improves bone status of ovariectomized mice. Am J Physiol Endocrinol Metab 2009;296:E1281-8.
- Ishikado A, Imanaka H, Suido H, Makino T./Osteoclast Growth Inhibitor, oral composition, and preventive or therapeutic agent for bone diseases, containing liposome encapsulated lactoferrin, Application#12084151, 2006, Pub #20090130191, 2009.
- Mohammadifar MA, Musavi SM, Kiumarsi A, Williams PA. Solution properties of targacanthin (water-soluble part of gum tragacanth exudate from Astragalus gossypinus). Int J Biol Macromol 2006;38:31-9.
- 15. Hagiwara A, Tanaka H, Tiwawech D, Shirai T, Ito N. Oral toxicity study of tragacanth gum in B6C3F1 mice: Development of squamous-cell hyperplasia in the forestomach and its reversibility. J Toxicol Environ Health 1991;34:207-18.
- Hagiwara A, Boonyaphiphat P, Kawabe M, Naito H, Shirai T, Ito N. Lack of carcinogenicity of tragacanth gum in B6C3F1 mice. Food Chem Toxicol 1992;30:673-9.
- Furlaneto FA, Nagata MJ, Fucini SE, Deliberador TM, Okamoto T, Messora MR. Bone healing in critical-size defects treated with bioactive glass/calcium sulfate: A histologic and histometric study in rat calvaria. Clin Oral Implants Res 2007;18:311-8.
- Pripatnanont P, Nuntanaranont T, Vongvatcharanon S. Proportion of deproteinized bovine bone and autogenous bone affects bone formation in the treatment of calvarial defects in rabbits. Int J Oral Maxillofac Surg 2009;38:356-62.
- Dodde R 2<sup>nd</sup>, Yavuzer R, Bier UC, Alkadri A, Jackson IT. Spontaneous bone healing in the rabbit. J Craniofac Surg 2000;11:346-9.
- Nagata MJ, Melo LG, Messora MR, Bomfim SR, Fucini SE, Garcia VG, *et al.* Effect of platelet-rich plasma on bone healing of autogenous bone grafts in critical-size defects. J Clin Periodontol 2009;36:775-83.
- Shand JM, Heggie AA, Holmes AD, Holmes W. Allogeneic bone grafting of calvarial defects: An experimental study in the rabbit. Int J Oral Maxillofac Surg 2002;31:525-31.
- 22. Mapara M, Thomas BS, Bhat KM. Rabbit as an animal model for experimental research. Dent Res J (Isfahan) 2012;9:111-8.
- 23. Sohn JY, Park JC, Um YJ, Jung UW, Kim CS, Cho KS, *et al.* Spontaneous healing capacity of rabbit cranial defects of various sizes. J Periodontal Implant Sci 2010;40:180-7.
- 24. Grey A, Banovic T, Zhu Q, Watson M, Callon K, Palmano K, *et al.* The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol 2004;18:2268-78.
- 25. Cornish J. Lactoferrin promotes bone growth. Biometals 2004;17:331-5.
- Grey A, Zhu Q, Watson M, Callon K, Cornish J. Lactoferrin potently inhibits osteoblast apoptosis, via an LRP1-independent pathway. Mol Cell Endocrinol 2006;251:96-102.
- 27. Malet A, Bournaud E, Lan A, Mikogami T, Tome D, Blais A. Bovine lactoferrin improves bone status of ovariectomized mice via immune function modulation. Bone 2011;48:1028-35.

Dental Research Journal / Dec 2012 / Vol 9 / Issue 7 (Supplement Issue 1)

- Guo HY, Jiang L, Ibrahim SA, Zhang L, Zhang H, Zhang M, et al. Orally administered lactoferrin preserves bone mass and microarchitecture in ovariectomized rats. J Nutr 2009;139:958-64.
- 29. Torres J, Tamimi FM, Tresguerres IF, Alkhraisat MH, Khraisat A, Lopez-Cabarcos E, *et al.* Effect of solely applied platelet-rich plasma on osseous regeneration compared to Bio-Oss: A morphometric and densitometric study on rabbit calvaria. Clin Implant Dent Relat Res 2008;10:106-12.
- Tamimi FM, Torres J, Tresguerres I, Clemente C, Lopez-Cabarcos E, Blanco LJ. Bone augmentation in rabbit calvariae: Comparative study between Bio-Oss and a novel beta-TCP/DCPD granulate. J Clin Periodontol 2006;33:922-8.
- 31. Baveye S, Elass E, Mazurier J, Spik G, Legrand D. Lactoferrin:

A multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med 1999;37:281-6.

- Verbeken D, Dierckx S, Dewettinck K. Exudate gums: Occurrence, production, and applications. Appl Microbiol Biotechnol 2003;63:10-21.
- Wang HL, Boyapati L. "PASS" principles for predictable bone regeneration. Implant Dent 2006;15:8-17.

**How to cite this article:** Paknejad M, Rokn AR, Yaraghi AS, Elhami F, Kharazifard MJ, Moslemi N. Histologic and histomorphometric evaluation of the effect of lactoferrin combined with anorganic bovine bone on healing of experimentally induced bony defects on rabbit calvaria. Dent Res J 2012;9:S75-80.

Source of Support: Nil. Conflict of Interest: None declared.

Announcement

#### Android App



A free application to browse and search the journal's content is now available for Android based mobiles and devices. The application provides "Table of Contents" of the latest issues, which are stored on the device for future offline browsing. Internet connection is required to access the back issues and search facility. The application is compatible with all the versions of Android. The application can be downloaded from https://market.android.com/details?id=comm.app.medknow. For suggestions and comments do write back to us.